Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CDXCNASDAQ:CRONOTCMKTS:STDAFNYSE:USNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDXCChromaDex$6.16$2.31▼$9.18$611.50M2.21818,844 shs554,788 shsCRONCronos Group$1.91$1.92$1.60▼$2.54$736.65M1.041.35 million shs1.11 million shsSTDAFSTADA Arzneimittel Aktiengesellschaft$110.42$110.42$75.15▼$115.00$6.88B0.38180 shsN/AUSNAUSANA Health Sciences$30.39-0.2%$28.37$23.10▼$48.85$567.07M0.63137,323 shs190,483 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDXCChromaDex0.00%0.00%0.00%0.00%+165.71%CRONCronos Group-1.04%-2.05%-10.75%+3.24%-18.38%STDAFSTADA Arzneimittel Aktiengesellschaft0.00%0.00%0.00%0.00%0.00%USNAUSANA Health Sciences-1.24%-1.15%+0.63%+10.45%-33.33%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCDXCChromaDex2.685 of 5 stars3.50.00.04.00.60.01.9CRONCronos Group2.7591 of 5 stars0.05.00.00.03.30.02.5STDAFSTADA Arzneimittel AktiengesellschaftN/AN/AN/AN/AN/AN/AN/AN/AUSNAUSANA Health Sciences3.921 of 5 stars2.01.00.03.22.11.73.8Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCDXCChromaDex 3.00Buy$9.03∞ UpsideCRONCronos Group 0.00N/AN/AN/ASTDAFSTADA Arzneimittel Aktiengesellschaft 0.00N/AN/AN/AUSNAUSANA Health Sciences 2.00Hold$36.0018.46% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCDXCChromaDex$99.60M0.00N/AN/A$0.38 per share0.00CRONCronos Group$117.61M6.26$0.00 per share4,104.70$2.90 per share0.66STDAFSTADA Arzneimittel Aktiengesellschaft$3.84B1.79$11.12 per share9.93$23.11 per share4.78USNAUSANA Health Sciences$854.50M0.66$3.77 per share8.07$27.92 per share1.09Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCDXCChromaDex-$4.94M$0.10787.290.00N/A1.62%4.85%2.70%N/ACRONCronos Group$41.08M$0.1314.6963.6743.3139.69%-0.07%-0.07%8/6/2025 (Estimated)STDAFSTADA Arzneimittel Aktiengesellschaft$292.15MN/A0.00∞N/AN/AN/AN/AN/AUSNAUSANA Health Sciences$42.03M$1.8216.7010.520.973.98%8.94%6.74%7/22/2025 (Estimated)Latest STDAF, CRON, CDXC, and USNA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025CRONCronos Group$0.01$0.02+$0.01$0.02$45.44 million$33.62 million4/22/2025Q1 2025USNAUSANA Health Sciences$0.70$0.73+$0.03$0.49$243.08 million$249.54 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCDXCChromaDexN/AN/AN/AN/AN/ACRONCronos GroupN/AN/AN/AN/AN/ASTDAFSTADA Arzneimittel AktiengesellschaftN/AN/AN/AN/AN/AUSNAUSANA Health SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCDXCChromaDexN/A2.952.35CRONCronos GroupN/A27.8026.75STDAFSTADA Arzneimittel Aktiengesellschaft2.231.540.99USNAUSANA Health SciencesN/A2.051.51Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCDXCChromaDex15.41%CRONCronos Group8.71%STDAFSTADA Arzneimittel AktiengesellschaftN/AUSNAUSANA Health Sciences54.25%Insider OwnershipCompanyInsider OwnershipCDXCChromaDex9.64%CRONCronos Group7.30%STDAFSTADA Arzneimittel AktiengesellschaftN/AUSNAUSANA Health Sciences0.63%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCDXCChromaDex12077.75 million69.02 millionOptionableCRONCronos Group450385.68 million357.53 millionOptionableSTDAFSTADA Arzneimittel Aktiengesellschaft12,50062.34 millionN/ANot OptionableUSNAUSANA Health Sciences1,70018.62 million18.51 millionOptionableSTDAF, CRON, CDXC, and USNA HeadlinesRecent News About These CompaniesUSNA vs. STVN: Which Stock Is the Better Value Option?June 18 at 12:41 PM | zacks.comUSANA Health (USNA) Upgraded to Buy: Here's What You Should KnowJune 17 at 1:00 PM | zacks.comIs USANA Health Sciences (USNA) Stock Undervalued Right Now?June 17 at 10:41 AM | zacks.com5 Low Price-to-Book Value Stocks That You Can Buy in JuneJune 17 at 10:05 AM | zacks.comUSANA Health Sciences, Inc. (NYSE:USNA) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?June 17 at 8:45 AM | finance.yahoo.comUSANA CEO Elected to Board of Direct Selling AssociationJune 17 at 7:17 AM | prnewswire.comUSANA Takes Home Five Best of State Awards, Including the Coveted Best of State StatueJune 12, 2025 | prnewswire.comUSANA Health Sciences, Inc. (NYSE:USNA) Director Sells $14,830.00 in StockJune 10, 2025 | marketbeat.comMillennium Management LLC Makes New Investment in USANA Health Sciences, Inc. (NYSE:USNA)June 8, 2025 | marketbeat.comReflecting On Personal Care Stocks’ Q1 Earnings: USANA (NYSE:USNA)June 4, 2025 | msn.comUSANA Executive Chairman Kevin Guest Celebrates National Outdoors Month with a Call to ...June 2, 2025 | gurufocus.comUSANA Executive Chairman Kevin Guest Celebrates National Outdoors Month with a Call to Reconnect with NatureJune 2, 2025 | prnewswire.comUSANA Health Sciences, Inc. (NYSE:USNA) COO Walter Noot Sells 6,291 SharesMay 30, 2025 | marketbeat.comAmeriprise Financial Inc. Has $2.75 Million Stock Position in USANA Health Sciences, Inc. (NYSE:USNA)May 30, 2025 | marketbeat.comUSANA Health Sciences (NYSE:USNA) Upgraded at Wall Street ZenMay 24, 2025 | marketbeat.comNorthern Trust Corp Acquires 19,266 Shares of USANA Health Sciences, Inc. (NYSE:USNA)May 24, 2025 | marketbeat.comUSANA Health Sciences, Inc. (NYSE:USNA) Shares Bought by Jane Street Group LLCMay 22, 2025 | marketbeat.comShareholders in USANA Health Sciences (NYSE:USNA) are in the red if they invested five years agoMay 21, 2025 | finance.yahoo.comUSANA Health Sciences, Inc. (NYSE:USNA) CFO Sells $134,666.28 in StockMay 13, 2025 | insidertrades.comUSNA Q1 Earnings Call: Product Expansion and Market Momentum Drive OutperformanceMay 13, 2025 | finance.yahoo.comUSANA Releases 2024 Sustainability ReportMay 8, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsMicron Joins Latest $200 Billion United States Investment By Gabriel Osorio-Mazilli | June 16, 2025View Micron Joins Latest $200 Billion United States Investment STDAF, CRON, CDXC, and USNA Company DescriptionsChromaDex NASDAQ:CDXCChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.Cronos Group NASDAQ:CRON$1.91 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.93 +0.02 (+1.05%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.STADA Arzneimittel Aktiengesellschaft OTCMKTS:STDAF$110.42 0.00 (0.00%) As of 10/24/2022STADA is a publicly traded, international company with a focus on the healthcare market, especially the pharmaceutical and in particular the generics market.USANA Health Sciences NYSE:USNA$30.39 -0.06 (-0.19%) Closing price 03:59 PM EasternExtended Trading$30.44 +0.04 (+0.14%) As of 06:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products. It also provides Celavive, a skin care regimen for various skin care types and ethnicities; and other products for prenatal, infant, and young child age groups. In addition, the company offers materials and online tools to assist associates in building their businesses, as well as in marketing products. It offers its products through retail stores and online. The company has a research collaboration agreement with Beijing University of Chinese Medicine; and National Sports Training Bureau. USANA Health Sciences, Inc. was founded in 1992 and is headquartered in Salt Lake City, Utah. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Chime’s Smart IPO: Half the Valuation, Double the Strength Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Tesla Bulls and Bears Collide: What Investors Should Know Qualcomm: A Technical Setup Is Emerging, and It's Bullish 330% Returns YTD: Is CoreWeave's Momentum Softening? Why Quantum Computing Inc. Is the Quiet Winner in Quantum Stocks 3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated Microsoft-OpenAI Rift May Cap Stock Upside Potential Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
